Form Type: 4/A

SEC EDGAR Link
Accession Number:0001209191-20-002418
Date:2019-12-26
Issuer: ADAPTIVE BIOTECHNOLOGIES CORP (ADPT)
Original Submission Date:2019-12-30

Reporting Person:

DOBMEIER ERIC
C/O ADAPTIVE BIOTECHNOLOGIES CORP.
SUITE 200 SEATTLE, WA 98102

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2019-12-26 M 15,000 a $6.32 15,000 direct
COMMON STOCK 2019-12-26 S 14,998 d $29.29 2 direct
COMMON STOCK 2019-12-26 S 2 d $29.91 0 direct
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
STOCK OPTION (RIGHT TO BUY) 6.32 2019-12-26 deemed execution date M 15,000 (d) 2026-10-18 common stock 15,000 $6.32 85,000 direct
Footnotes
IDfootnote
f1 the transactions reported in this form 4 were effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on november 25, 2019.
f2 the price reported for this transaction is a weighted-average price. the shares were sold in multiple transactions ranging from $28.85 to 29.73, inclusive. the reporting person undertakes to provide to adaptive biotechnologies corporation, any security holder of adaptive biotechnologies corporation, or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this form 4.
f3 the options vested with respect to 1/4 of the reporting person's shares on september 28, 2017, with an additional 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
WhaleWisdom Logo

Elevate your investments